View Older Stories View More Recent Stories

Sep 14, 2015 10:30AM Amarantus Receives Orphan Drug Designation From the U.S. Food and Drug Administration for MANF for the Treatment of Retinal Artery Occlusion
Sep 14, 2015 10:30AM Amarantus Receives Orphan Drug Designation From the U.S. Food and Drug Administration for MANF for the Treatment of Retinal Artery Occlusion
Sep 3, 2015 07:05AM Amarantus Announces Results of Annual Meeting
Sep 3, 2015 07:05AM Amarantus Announces Results of Annual Meeting
Aug 26, 2015 12:30PM Amarantus Moves Annual Meeting Date Forward to September 2, 2015
Aug 20, 2015 08:35AM Amarantus Announces Issuance of United States Patent Covering Proprietary Compositions of Matter and Methods of Use for Product Candidate MANF
Aug 20, 2015 08:35AM Amarantus Announces Issuance of United States Patent Covering Proprietary Compositions of Matter and Methods of Use for Product Candidate MANF
Aug 17, 2015 08:05AM Amarantus Reports Second Quarter 2015 Financial Results and Business Overview
Aug 17, 2015 08:05AM Amarantus Reports Second Quarter 2015 Financial Results and Business Overview
Aug 7, 2015 05:05PM Amarantus Announces Adjournment of Annual Meeting
Aug 7, 2015 05:05PM Amarantus Announces Adjournment of Annual Meeting
Aug 5, 2015 08:50AM Amarantus Announces a New Eltoprazine Publication Confirming the Long-Term Efficacy and Elucidating the Mechanism of Action in PD-LID
Aug 5, 2015 08:50AM Amarantus Announces a New Eltoprazine Publication Confirming the Long-Term Efficacy and Elucidating the Mechanism of Action in PD-LID
Aug 3, 2015 05:30PM Amarantus Announces Adjournment of Annual Meeting
Aug 3, 2015 05:30PM Amarantus Announces Adjournment of Annual Meeting
Aug 3, 2015 06:00AM Amarantus BioScience, U.S. Army and Rutgers University in Partnership to Expand Development of Engineered Skin Substitute (ESS) for the Treatment of Severe Thermal Burn Wounds
Aug 3, 2015 06:00AM Amarantus BioScience, U.S. Army and Rutgers University in Partnership to Expand Development of Engineered Skin Substitute (ESS) for the Treatment of Severe Thermal Burn Wounds
Jul 29, 2015 07:35AM Amarantus Announces Publication of a Clinical Study of MSPrecise(R) Diagnostic for Identification of Relapsing-Remitting Multiple Sclerosis (RRMS) in the Journal GENE
Jul 29, 2015 07:35AM Amarantus Announces Publication of a Clinical Study of MSPrecise(R) Diagnostic for Identification of Relapsing-Remitting Multiple Sclerosis (RRMS) in the Journal GENE
Jul 27, 2015 07:35AM Amarantus Diagnostics Establishes Strategic Advisory Committee
Jul 27, 2015 07:35AM Amarantus Diagnostics Establishes Strategic Advisory Committee
Jul 22, 2015 10:30AM Amarantus Diagnostics Meets Primary and Secondary Endpoints in Blinded, Multi-Center LP-002 Clinical Study for LymPro(R) Blood Diagnostic for Alzheimer's Disease and Confirms LymPro's Fit-Fo
Jul 22, 2015 10:30AM Amarantus Diagnostics Meets Primary and Secondary Endpoints in Blinded, Multi-Center LP-002 Clinical Study for LymPro(R) Blood Diagnostic for Alzheimer's Disease and Confirms LymPro's Fit-Fo
Jul 20, 2015 07:05AM Amarantus Announces First Patient Dosed in Eltoprazine Phase 2b Study for Treatment of Parkinson's Disease Levodopa-Induced Dyskinesia
Jul 20, 2015 07:05AM Amarantus Announces First Patient Dosed in Eltoprazine Phase 2b Study for Treatment of Parkinson's Disease Levodopa-Induced Dyskinesia
Jul 15, 2015 07:05AM Amarantus Completes Acquisition of ESS From Lonza for the Treatment of Severe Burns
Jul 15, 2015 07:05AM Amarantus Completes Acquisition of ESS From Lonza for the Treatment of Severe Burns
Jul 13, 2015 07:05AM Amarantus to Commence Trading on the OTCQX Marketplace Under Existing Ticker Symbol AMBS
Jul 13, 2015 07:05AM Amarantus to Commence Trading on the OTCQX Marketplace Under Existing Ticker Symbol AMBS
Jul 13, 2015 07:00AM OTC Markets Group Welcomes Amarantus BioScience Holdings to OTCQX
Jun 30, 2015 08:35AM Amarantus Announces Issuance of United States Patent No. 9,066,903 Covering Proprietary Methods of Administration of Eltoprazine for the Treatment of Parkinson's Disease
Jun 30, 2015 08:35AM Amarantus Announces Issuance of United States Patent No. 9,066,903 Covering Proprietary Methods of Administration of Eltoprazine for the Treatment of Parkinson's Disease
Jun 15, 2015 07:05AM Amarantus Announces Presentation of Eltoprazine Phase 1/2a Clinical Data at the 19th International Congress of Parkinson's Disease and Movement Disorders
Jun 15, 2015 07:05AM Amarantus Announces Presentation of Eltoprazine Phase 1/2a Clinical Data at the 19th International Congress of Parkinson's Disease and Movement Disorders
Jun 10, 2015 08:05AM Amarantus to Present at the BIO International Convention
Jun 10, 2015 08:05AM Amarantus to Present at the BIO International Convention
Jun 9, 2015 04:05PM Amarantus Completes Capital Restructuring in Preparation for National Exchange Listing
Jun 9, 2015 04:05PM Amarantus Completes Capital Restructuring in Preparation for National Exchange Listing
Jun 9, 2015 10:58AM Amarantus Diagnostics Announces Acceptance of Two Late-Breaking Abstracts on LymPro Test(R) Data at the 2015 Alzheimer's Association International Conference(R)
Jun 9, 2015 10:58AM Amarantus Diagnostics Announces Acceptance of Two Late-Breaking Abstracts on LymPro Test(R) Data at the 2015 Alzheimer's Association International Conference(R)
Jun 5, 2015 07:35AM Amarantus Opens First Clinical Trial Site and Commences Patient Enrollment for Lead Product Candidate Eltoprazine's Phase 2b Study in Parkinson's Disease Levodopa-Induced Dyskinesia
Jun 5, 2015 07:35AM Amarantus Opens First Clinical Trial Site and Commences Patient Enrollment for Lead Product Candidate Eltoprazine's Phase 2b Study in Parkinson's Disease Levodopa-Induced Dyskinesia
May 26, 2015 07:05AM Amarantus to Present at the Fourth Annual SeeThru Equity Microcap Investor Conference on May 28, 2015
May 26, 2015 07:05AM Amarantus to Present at the Fourth Annual SeeThru Equity Microcap Investor Conference on May 28, 2015
May 22, 2015 07:05AM Amarantus Effects Capital Restructuring in Anticipation of National Exchange Listing
May 22, 2015 07:05AM Amarantus Effects Capital Restructuring in Anticipation of National Exchange Listing
May 21, 2015 07:05AM Amarantus Enters Into CRO Agreement With Chiltern International to Commence Phase 2b Clinical Development of Eltoprazine in Parkinson's Disease Levodopa-Induced Dyskinesia
May 21, 2015 07:05AM Amarantus Enters Into CRO Agreement With Chiltern International to Commence Phase 2b Clinical Development of Eltoprazine in Parkinson's Disease Levodopa-Induced Dyskinesia
May 20, 2015 07:05AM Amarantus Reports First Quarter 2015 Financial Results and Business Overview
May 20, 2015 07:05AM Amarantus Reports First Quarter 2015 Financial Results and Business Overview
View More Recent Stories View Older Stories